Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics


Xeris Pharmaceuticals, Inc. (XERS)

Today's Latest Price: $4.18 USD

0.03 (-0.71%)

Updated Dec 2 4:00pm

Add XERS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

XERS Stock Summary

  • Xeris Pharmaceuticals Inc's stock had its IPO on June 21, 2018, making it an older stock than merely 6.62% of US equities in our set.
  • As for revenue growth, note that XERS's revenue has grown 792.08% over the past 12 months; that beats the revenue growth of 99.02% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for XERS comes in at -58.32% -- higher than that of only 6.29% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Xeris Pharmaceuticals Inc, a group of peers worth examining would be AVGR, EYPT, RWLK, HTGM, and MBII.
  • Visit XERS's SEC page to see the company's official filings. To visit the company's web site, go to www.xerispharma.com.

XERS Stock Price Chart Interactive Chart >

Price chart for XERS

XERS Price/Volume Stats

Current price $4.18 52-week high $9.69
Prev. close $4.21 52-week low $1.42
Day low $4.06 Volume 1,566,200
Day high $4.27 Avg. volume 1,855,629
50-day MA $5.20 Dividend yield N/A
200-day MA $3.89 Market Cap 204.72M

Xeris Pharmaceuticals, Inc. (XERS) Company Bio


Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.


XERS Latest News Stream


Event/Time News Detail
Loading, please wait...

XERS Latest Social Stream


Loading social stream, please wait...

View Full XERS Social Stream

Latest XERS News From Around the Web

Below are the latest news stories about Xeris Pharmaceuticals Inc that investors may wish to consider to help them evaluate XERS as an investment opportunity.

Xeris Looks Like A High-Quality Platform Play As Gvoke Sales Increase

Xeris Pharmaceuticals (XERS) is a company that got on my radar about two weeks ago. Xeris is already a commercial stage biotech, and this past week saw a big rally in the stock as sales of its lead product, Gvoke, have started picking up. Figure 1: Xeris Stock Chart (source:...

Andy Jones on Seeking Alpha | August 31, 2020

FDA warns Xeris over Gvoke ad; shares down 13%

Xeris Pharmaceuticals ([[XERS]] -13.3%) is down on more than double normal volume in apparent reaction to its receipt of an FDA Warning Letter concerning its promotion of Gvoke (glucagon), approved in the U.S. a year ago for the treatment of severe low blood sugar in diabetics at least two years...

Seeking Alpha | August 20, 2020

Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Yahoo Finance | August 18, 2020

Earnings Scheduled For August 10, 2020

Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is exp...

Benzinga | August 10, 2020

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on July 29, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares of its common stock to 4 new employees under Xeris’ Inducement Equity Plan.

Yahoo | July 31, 2020

Read More 'XERS' Stories Here

XERS Price Returns

1-mo -5.86%
3-mo -16.23%
6-mo -13.55%
1-year -52.50%
3-year N/A
5-year N/A
YTD -40.71%
2019 -58.53%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching XERS

Want to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:

Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7739 seconds.